Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 62332-494

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 62332-494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lurasidone-figure-1.jpg (Lurasidone Figure 1)

Impact of other drugs on the pharmacokinetics of Lurasidone is being evaluated in this text. The interacting drugs and their fold change and 90% CI with respect to Lurasidone's PK are mentioned. Ketoconazole (400 mg/day) is a strong CYP3A4 inhibitor and showed an increase in Cmax and Auc. Diltiazem (240 mg/day) is a moderate CYP3A4 inhibitor, and no change was observed in Cmax while Auc decreased. Rifampin (600 mg/day) is a strong CYP3A4 inducer and showed a decrease in Cmax and Auc. Lithium (600 mg BID) showed an increase in Cmax and Auc.*

FDA Label Image

Lurasidone-figure-2.jpg (Lurasidone Figure 2)

This is a table showing the PK fold change and 90% C for interacting drugs belonging to different categories such as P-gp substrates, CYPIA4 substrates, Oral contraceptive, and Lithium. Some drugs listed in the table are Digoxin, Midazolam, Ethinyi Estradiol, Norelgestromin, and Lithium. The table also highlights the Crmax and Auc measurements for some of these drugs along with a measure of change relative to the interactive drug alone.*

FDA Label Image

Lurasidone-figure-3.jpg (Lurasidone Figure 3)

FDA Label Image

Lurasidone HCl Tabs mg 120

FDA Label Image

Lurasidone HCl Tabs mg 20

This text is a description of a medication called Lurasidone Hydrochloride in tablet form. It contains 20mg of rasions hyiocorte and is manufactured by Aembc Phamsceutcas Linitad. The recommended storage temperature is 15-30°C and it is manufactured for N Phamaceutcas, inc. The NDC (National Drug Code) for this medication is 62332-494-30 and the GTIN (Global Trade Item Number) is 00362332494309. The rest of the text includes various codes and technical information related to the manufacturing and packaging of the medication.*

FDA Label Image

Lurasidone HCl Tabs mg 40

The text appears to be a description of a medication called Lurasidone Hydrochloride. It provides information about the dosage and storage of the medicine. However, some of the information is unclear and badly formatted, making it difficult to understand.*

FDA Label Image

Lurasidone HCl Tabs mg 60

Lurasidone Hydrochloride Tablets | 60 mg is a medication with a recommended dose mentioned in the package insert. It should be stored at a temperature between 15° and 30°C and handled by Aombe Pharmaceuticals Ui for manufacture and Eme Pharmaceuticals for distribution. The text also includes information on the medication's UPC, lot number, and coding area but is lacking clear readability as it appears to be .*

FDA Label Image

Lurasidone HCl Tabs mg 80

This is a description of a medication labeled Lurasidone Hydrochloride, in tablet form, manufactured by Otsuka Pharmaceutical Limited. Each tablet contains 0mg of Rasione Hcocherde which is equivalent to 7445mg of Krascore. The dosage is not specified and it is advised to refer to the package insert. The medication should be stored at temperatures within 15°C to 37°C (59°F to 89°F). The manufacturer's address is provided, as well as the NDC number, and GTIN number. The rest of the text is not available or unreadable.*

FDA Label Image

Lurasidone-str.jpg (Lurasidone Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.